title: The influence of a thyroxine supplemented diet on selected hepatic redox equilibrium markers, liver morphology and the serum lipid profile in rats treated with doxorubicin.
abstract: BACKGROUND
  Cytotoxicity of doxorubicin (DOX) - an anticancer drug, mostly results from reactive oxygen species (ROS) generation. Some enzymes catalyzing this process and enzymes of antioxidant defense are regulated by iodothyronine hormones. Thus, disorders in iodothyronine hormone status may affect doxorubicin-induced redox imbalance and anabolic/catabolic disorders. The aim of this study was to evaluate the influence of doxorubicin and thyroxine (T4) associated treatment on liver morphology, markers of oxidative stress and plasma lipid parameters.
  
  
  METHODS
  Rats were intraperitoneally treated with doxorubicin (1.5 mg/kg) once a week for ten weeks. Thyroxine was simultaneously given in drinking water (0.2 or 2.0 mg/l) for 14 weeks.
  
  
  RESULTS
  There were higher hepatic level of malonyldialdehyde (MDA) of all tested groups and at the same time in rats treated with DOX plus T4 lower concentrations of total glutathione compared to controls were observed. Morphology of liver did not show any features of necrosis or steatosis but a decrease of glycogen content in T4+DOX groups compared to DOX treatment was observed. The concomitant administration of a lower dose of thyroxine and doxorubicin decreased triglycerides (TG) and increased LDL level compared to the DOX group.
  
  
  CONCLUSIONS
  Thyroxin supplementation caused redox equilibrium disorders and oxidative stress in liver of rats receiving DOX. The study revealed the normalizing influence of thyroxin on glycogen deposits that were observed after doxorubicin treatment. Apart from an adverse impact of thyroxine administration on LDL in rats treated with doxorubicin, a beneficial effect of lower dose of thyroxine on serum TG level was revealed.
authors.affiliation: Medical Biology Unit, Medical University of Lublin, Lublin, Poland. agnieszka.korga@umlub.pl
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Korga
authors.forename: Jarosław
authors.initials: J
authors.lastname: Dudka
authors.forename: Franciszek
authors.initials: F
authors.lastname: Burdan
authors.forename: Lech
authors.initials: L
authors.lastname: Wronecki
authors.forename: Jadwiga
authors.initials: J
authors.lastname: Sierocinska-Sawa
authors.forename: Magdalena
authors.initials: M
authors.lastname: Iwan
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Korobowicz-Markiewicz
authors.forename: Elżbieta
authors.initials: E
authors.lastname: Korobowicz
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D019587:Dietary Supplements; D004317:Doxorubicin / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D007274:Injections, Intraperitoneal; D008077:Lipoproteins, LDL / Q000097:blood* / Q000187:drug effects; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D010084:Oxidation-Reduction; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism; D013974:Thyroxine / Q000008:administration & dosage* / Q000097:blood; D014280:Triglycerides / Q000097:blood*
chemical_list: D000903:Antibiotics, Antineoplastic; D008077:Lipoproteins, LDL; D017382:Reactive Oxygen Species; D014280:Triglycerides; D004317:Doxorubicin; D013974:Thyroxine